Bicara Therapeutics Inc. BCAX
8.96 USD +1.03 (+12.99%)
At closeNov 3, 2026, 4:33 PM EST
8.96 0.00 +0.00%
After hours · Nov 3, 4:33 PM ET
7.90 Day range 9.48
7.87 52-week range 30.99
- YTD
- -46.76%
- 1 year
- -43.93%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.67 +298.1% upside
Now 8.96
- Target (low)
- 20.00
- Target (mean)
- 35.67
- Target (high)
- 45.00
Ratings (0m) 14 13 buy · 1 hold · 0 sell
- Strong buy3
- Buy10
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 14
- 2 months ago 16
- 3 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.82167 | -0.97 – -0.42 | -0.67 | -22.6% | 0 | 0.0% | 12 |
| Next quarter | -0.85417 | -0.97 – -0.47 | -0.68 | -25.6% | 0 | 0.0% | 12 |
| Current year | -3.39 | -3.68 – -2.65 | -2.52 | -34.4% | 0 | 0.0% | 12 |
| Next year | -3.52 | -4.73 – -1.86 | -3.39 | -4.0% | 0 | 0.0% | 11 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | BTIG | Reiterated | Buy | Buy |
| Aug 19, 2026 | BMO Capital | Initiated | — | Outperform |
| Aug 12, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Aug 12, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Aug 12, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 12, 2026 | Mizuho | Maintained | Neutral | Neutral |
| Aug 12, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 12, 2026 | BTIG | Maintained | Buy | Buy |
| May 12, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| May 12, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 11, 2026 | Guggenheim | Initiated | — | Buy |
| Mar 31, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Mar 31, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Mar 31, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Mar 31, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Mar 31, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 25, 2026 | B of A Securities | Initiated | — | Buy |
| Jan 29, 2026 | Citizens | Initiated | — | Market Outperform |
| Jan 13, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jan 8, 2026 | BTIG | Initiated | — | Buy |
| Dec 18, 2025 | Mizuho | Initiated | — | Neutral |
| Nov 11, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 22, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 19, 2025 | Piper Sandler | Initiated | — | Overweight |
| May 23, 2025 | Wells Fargo | Upgrade | Underweight | Equal-Weight |
| May 16, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 17, 2025 | Wells Fargo | Initiated | — | Underweight |
| Apr 7, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 13, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Feb 12, 2025 | Wedbush | Reiterated | Outperform | Outperform |